Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue TOPIC T1, 2001, Pages 1-8

  Douthwaite, Stephen ^a   Champney, W Scott ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYL GROUP; ANTIINFECTIVE AGENT; AZITHROMYCIN; CARBAMIC ACID; CETHROMYCIN; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; HMR 3004; HMR 3562; HMR 3787; KETOLIDE; MACROLIDE; RIBOSOME RNA; ROXITHROMYCIN; RU 56006; RU 66252; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; PROTEIN SYNTHESIS INHIBITION; RIBOSOME;

EID: 0034763651     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.suppl_2.1     Document Type: Article

References (49)

1. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995
2. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
3. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999
4. Susceptibility of 1100 Streptococcus pneumoniae strains isolated in 1997 from seven Latin American and Caribbean countries
5. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998
6. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification
7. Erythromycin resistance by ribosome modification
8. Macrolide resistance conferred by base substitutions in 23S rRNA
9. New research in macrolides and ketolides since 1997
10. The in vitro activity of ABT-773, a new ketolide antimicrobial agent
11. Comparative antimicrobial activity and kill-curve investigations of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains
12. In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
13. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents
14. Ketolide treatment of Haemophilus influenzae experimental pneumonia
15. In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany
16. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas
17. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia
18. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae
19. Susceptibilities of Legionella spp. to newer antimicrobials in vitro
20. The new macrolide antibiotics: Azithromycin, clarithromycin, dirithromycin, and roxithromycin
21. The development of macrolides: Clarithromycin in perspective
22. Ketolides: New semisynthetic 14-membered-ring macrolides
23. Beta-keto-ester chemistry and ketolides. Synthesis and antibacterial activity of 2-halogeno, 2-methyl and 2,3 enol-ether ketolides
24. Ketolides - Telithromycin, an example of a new class of antimicrobial agents
25. ABT-773: A new ketolide antibiotic
26. Studies of the novel ketolide ABT-773: Transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae
27. Chemistry and mode of action of macrolides
28. Inhibition of translation and 50S ribosomal subunit formation in S. aureus cells by 11 different ketolide antibiotics
29. Bacterial ribosomal subunit synthesis: A novel antibiotic target
30. Structure-activity relationships for six ketolide antibiotics
31. Erythromycin inhibition of 50S ribosomal subunit formation in Escherichia coli cells
32. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA
33. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre
34. Structural analysis of RNA using chemical and enzymatic probing monitored by primer extension
35. Macrolide-ketolide inhibition of MLS resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA
36. The complete atomic structure of the large ribosomal subunit at 2.4 Å resolution
37. Crystal structure of the ribosome at 5.5 Å resolution
38. The database of ribosomal cross links
39. Lessons from an evolving rRNA: 16S and 23S rRNA structures from a comparative perspective
40. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates
41. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: Influences of resistance mechanisms and methodological factors
42. In vitro activities of the novel ketolide telithromycin (HMR 3647) against erythromycin-resistant Streptococcus species
43. B resistance phenotype
44. Mechanisms of bacterial resistance to macrolide antibiotics
45. Mutations in 23S rRNA and L4 ribosomal protein account for resistance in pneumococcal strains selected in vitro by macrolide passage
46. Safeguarding future antimicrobial options: Strategies to minimize resistance
47. A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin
48. Inducible or constitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin